AlphaQuest LLC Boosts Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

AlphaQuest LLC increased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 106.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 4,540 shares of the biopharmaceutical company’s stock after purchasing an additional 2,338 shares during the period. AlphaQuest LLC’s holdings in Agios Pharmaceuticals were worth $149,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. State Street Corp lifted its position in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Agios Pharmaceuticals in the third quarter worth about $33,767,000. BNP Paribas Financial Markets lifted its position in shares of Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock worth $531,000 after buying an additional 1,570 shares in the last quarter. FMR LLC lifted its position in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after buying an additional 33,546 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the third quarter worth about $892,000.

Analyst Ratings Changes

A number of equities research analysts have issued reports on AGIO shares. Scotiabank upped their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. HC Wainwright started coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 price objective on the stock. Finally, StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $56.57.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $31.99 on Tuesday. The business’s 50 day moving average price is $33.67 and its 200-day moving average price is $41.67. Agios Pharmaceuticals, Inc. has a fifty-two week low of $27.14 and a fifty-two week high of $62.58. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 2.82 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.